Ascentage Pharma Group Corp. Ltd. said two of its novel candidates have been included in the 2025 Chinese Society of Clinical Oncology Guidelines, including its in-house developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which is under review in China and could be the first domestically approved Bcl-2 inhibitor and the second global approval.
Nippon Shinyaku Co. Ltd. has divulged azaindole compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, rheumatoid arthritis, psoriasis, spinal cord injury, Behçet’s disease, atopic dermatitis and idiopathic pulmonary fibrosis, among others.
Onward Therapeutics SA’s subsidiary Emercell SAS has received investigational medicinal product dossier (IMPD) approval from the EMA to initiate a phase I trial of OT-C001, an allogeneic natural killer (NK) cell therapy, in combination with an anti-CD20 monoclonal antibody, rituximab.
Ascentage Pharma Group Corp. Ltd. said two of its novel candidates have been included in the 2025 Chinese Society of Clinical Oncology Guidelines, including its in-house developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which is under review in China and could be the first domestically approved Bcl-2 inhibitor and the second global approval.
Richter transformation (RT) refers to the occurrence of an aggressive and treatment-resistant lymphoma that arises from the progression of chronic lymphocytic leukemia (CLL) and is associated with a poor prognosis. Disruptive mutations in the BCL6 co-repressor (Bcor) gene are found in up to 2% of CLL cases and often occur alongside Notch1 mutations, a common molecular alteration linked to RT. This co-occurrence points to a possible cooperative role in driving disease progression.
At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ligand-directed degrader (LDD) of B-cell lymphoma 6 protein (BCL6), BMS-986458, for the treatment of B-cell non-Hodgkin lymphoma.
Allogenica SAS has been awarded a €2.5 million (US$2.7 million) grant under the French government’s France 2030 program to help advance its universal CAR T candidate, XL-001, for CD19-positive hematologic cancers.
Researchers from Soochow University and affiliated organizations presented data from a study that aimed to investigate the role of cyclic GMP-AMP synthase (cGAS) in tumorigenesis and tumor progression.
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
The Wiskott-Aldrich syndrome protein (WASp) is expressed exclusively in hematopoietic cells and presents either an autoinhibited or activated conformation. EG-011 is a first-in-class activator of the autoinhibited form of WASp designed for the treatment of hematological cancers.
